Non-Monograph Drugs Interim Marketing Preservation Urged By CHPA
This article was originally published in The Tan Sheet
Executive Summary
FDA's proposed rule on "material time and material extent" criteria for inclusion of drug conditions in the OTC review would "effectively terminate" the monograph process, CHPA maintains in a March 22 letter to the agency.
You may also be interested in...
FDA “Material Time, Material Extent” Rule May Be Cloudy For Sunscreens
Interim marketing for OTC drugs or "conditions" in the U.S. subject to a final or new monograph is barred under FDA's final rule on "material time, material extent" criteria
FDA “Material Time, Material Extent” Rule May Be Cloudy For Sunscreens
Interim marketing for OTC drugs or "conditions" in the U.S. subject to a final or new monograph is barred under FDA's final rule on "material time, material extent" criteria
FDA “Material Time, Material Extent” Rule May Be Cloudy For Sunscreens
Interim marketing for OTC drugs or "conditions" in the U.S. subject to a final or new monograph is barred under FDA's final rule on "material time, material extent" criteria